Consensus Prime Medicine, Inc.

Equities

PRME

US74168J1016

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 06:00:00 16/04/26 am AEST			5-day change	1st Jan Change
3.790 ^USD	+2.43%		+7.06%	+9.22%

19/03	Prime Medicine, Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
12/03	Oppenheimer Initiates Prime Medicine at Outperform With $11 Price Target	MT

Evolution of the Average Target: Prime Medicine, Inc.

Evolution of the Target Price: Prime Medicine, Inc.

Changes in Analyst Recommendations: Prime Medicine, Inc.

3e6337688751b.bEr2CHFUXeSf_AsstB_-uv1M5MIoy14hLrzeM_KF5ac.KRueZQgFa67WqWhd5223l7coko1esWdvGfeKUaqxqeBbKJxyBScXj_eFeA~3f5644e6f9ac86adbf609edb6f8f3e01

Analysts' recommendations: Prime Medicine, Inc.

12/03	Oppenheimer Initiates Prime Medicine at Outperform With $11 Price Target	MT
24/12	LifeSci Initiates Prime Medicine at Outperform With $6 Price Target	MT
11/08/25	Chardan Research Adjusts Prime Medicine Price Target to $10 From $12, Maintains Buy Rating	MT
27/05/25	Citigroup Downgrades Prime Medicine to Neutral From Buy, Adjusts Price Target to $1.50 From $10	MT
20/05/25	JPMorgan Downgrades Prime Medicine to Neutral From Overweight	MT
20/05/25	HC Wainwright Downgrades Prime Medicine to Neutral From Buy	MT
20/05/25	Chardan Lowers Price Target on Prime Medicine to $12 From $16, Keeps Buy Rating	MT
20/05/25	Wedbush Adjusts Prime Medicine Price Target to $8 From $13, Maintains Outperform Rating	MT
20/03/25	Chardan Raises Price Target on Prime Medicine to $16 From $15, Keeps Buy Rating	MT
19/03/25	Wedbush Adjusts Prime Medicine Price Target to $13 From $12, Maintains Outperform Rating	MT
10/12/24	JMP Securities Initiates Prime Medicine at Market Outperform With $10 Price Target	MT
20/05/24	HC Wainwright Starts Coverage on Prime Medicine With Buy Rating, $10 Price Target	MT
16/05/24	Citigroup Upgrades Prime Medicine at Buy From Neutral With $10 Price Target	MT
14/05/24	JPMorgan Adjusts Price Target on Prime Medicine to $15 From $16, Keeps Overweight Rating	MT
22/04/24	Chardan Initiates Prime Medicine With Buy Rating, Price Target is $17	MT
22/04/24	Chardan Initiates Prime Medicine at Buy With $17 Price Target	MT
04/04/24	Wedbush Initiates Prime Medicine With Outperform Rating, $12 PT; Notes Positive Long-Term Outlook on Gene Editing Platform	MT
06/03/24	Guggenheim Cuts Prime Medicine's Price Target to $20 From $24, Maintains Buy Rating	MT
12/12/23	Morgan Stanley Cuts Price Target on Prime Medicine to $12 From $18, Keeps Equalweight Rating	MT
09/10/23	BMO Capital Starts Prime Medicine at Outperform, $19 Price Target	MT
06/09/23	Jones Trading Starts Prime Medicine at Buy With $20 Price Target	MT
14/08/23	Morgan Stanley Adjusts Price Target on Prime Medicine to $19 From $21, Keeps Equalweight Rating	MT
31/07/23	Guggenheim Starts Prime Medicine at Buy With $24 Price Target	MT
18/04/23	Stifel Initiates Prime Medicine at Hold With $18 Price Target	MT
25/01/23	Morgan Stanley Adjusts Price Target on Prime Medicine to $21 From $23, Maintains Equal-Weight Rating	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	PRIME MEDICINE, INC.					+86.94%
	ARGENX SE					+19.32%
	WUXI APPTEC CO., LTD.					+26.35%
	INSMED INCORPORATED					+38.43%
	BIONTECH SE					+34.2%
	WUXI BIOLOGICS (CAYMAN) INC.					+23.81%
	GENMAB A/S					+21.18%
	AKESO, INC.					+26.3%
	SUMMIT THERAPEUTICS INC.					+45.52%
	SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.					+9.9%
	Average					+33.19%
	Weighted average by Cap.					+27.05%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

3.790USD

Average target price

6.917USD

Spread / Average Target

+82.50%

High Price Target

11.00USD

Spread / Highest target

+190.24%

Low Price Target

4.250USD

Spread / Lowest Target

+12.14%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Oppenheimer
LifeSci Capital
Chardan Research
Citigroup
HC Wainwright
JPMorgan Chase
Wedbush
JMP Securities
Guggenheim
Morgan Stanley
BMO Capital
JonesTrading Institutional Services
Stifel Nicolaus
Jefferies & Co.
Goldman Sachs